The genome-wide distribution of FST showed that the most significantly variation was a 3,200 bp deletion (chromosome 2: 163,312,001–163,315,200 bp) that overlapped with the CATHL3 gene (encoding cathelicidin 3) and a 3,600 bp duplication (chromosome 5: 55,372,001–55,375,600 bp) overlapping with the DMBT1 gene (encoding deleted in malignant brain tumors 1). This evidence concerns the gene DMBT1 and brain cancer.